Ferguson Kathleen A, Cartwright Rosalind, Rogers Robert, Schmidt-Nowara Wolfgang
Division of Respirology, University of Western Ontario, London Health Sciences Centre, Canada.
Sleep. 2006 Feb;29(2):244-62. doi: 10.1093/sleep/29.2.244.
We conducted an evidence-based review of literature regarding use of oral appliances (OAs) in the treatment of snoring and obstructive sleep apnea syndrome (OSA) from 1995 until the present. Our structured search revealed 141 articles for systematic scrutiny, of which 87 were suitable for inclusion in the evidence base, including 15 Level I to II randomized controlled trials and 5 of these trials with placebo-controlled treatment. The efficacy of OAs was established for controlling OSA in some but not all patients with success (defined as no more than 10 apneas or hypopneas per hour of sleep) achieved in an average of 52% of treated patients. Effects on sleepiness and quality of life were also demonstrated, but improvements in other neurocognitive outcomes were not consistent. The mechanism of OA therapy is related to opening of the upper airway as demonstrated by imaging and physiologic monitoring. Treatment adherence is variable with patients reporting using the appliance a median of 77% of nights at 1 year. Minor adverse effects were frequent whereas major adverse effects were uncommon. Minor tooth movement and small changes in the occlusion developed in some patients after prolonged use, but the long-term dental significance of this is uncertain. In comparison to continuous positive airway pressure (CPAP), OAs are less efficacious in reducing the apnea hypopnea index (AHI), but OAs appear to be used more (at least by self report), and in many studies were preferred over CPAP when the treatments were compared. OAs have also been compared favorably to surgical modification of the upper airway (uvulopalatopharyngoplasty, UPPP). Comparisons between OAs of different designs have produced variable findings. The literature of OA therapy for OSA now provides better evidence for the efficacy of this treatment modality and considerable guidance regarding the frequency of adverse effects and the indications for use in comparison to CPAP and UPPP.
我们对1995年至今使用口腔矫治器(OAs)治疗打鼾和阻塞性睡眠呼吸暂停综合征(OSA)的文献进行了循证综述。我们的结构化检索发现了141篇文章进行系统审查,其中87篇适合纳入证据库,包括15项I至II级随机对照试验,其中5项为安慰剂对照治疗试验。已证实OAs对部分但并非所有患者控制OSA有效(定义为每小时睡眠中呼吸暂停或低通气不超过10次),平均52%的接受治疗患者取得成功。对嗜睡和生活质量的影响也得到了证实,但在其他神经认知结果方面的改善并不一致。影像学和生理监测表明,OA治疗的机制与上气道开放有关。治疗依从性各不相同,患者报告在1年中使用该矫治器的夜间中位数为77%。轻微不良反应常见,而严重不良反应不常见。一些患者长期使用后出现轻微牙齿移动和咬合的小变化,但其长期牙科意义尚不确定。与持续气道正压通气(CPAP)相比,OAs在降低呼吸暂停低通气指数(AHI)方面效果较差,但OAs的使用似乎更多(至少根据自我报告),并且在许多研究中,与CPAP相比,患者更倾向于选择OAs。与上气道手术改良(悬雍垂腭咽成形术,UPPP)相比,OAs也具有优势。不同设计的OAs之间的比较结果各异。目前,关于OAs治疗OSA的文献为这种治疗方式的疗效提供了更好的证据,并在不良反应发生频率以及与CPAP和UPPP相比的使用指征方面提供了相当多的指导。